[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100640340":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":23,"centralContacts":27,"locations":36,"responsibleParty":120,"collaborators":122,"id":125,"slug":10,"hasResults":126,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":130,"eligibilityCriteria":131,"healthyVolunteers":126,"sex":132,"minAge":10,"maxAge":10,"enrollmentInfo":133,"targetDuration":10,"studyType":136,"phases":10,"briefSummary":137,"conditions":138,"keywords":140,"overallStatus":144,"whyStopped":10,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":154},{"fullName":5,"class":6},"Assistance Publique - Hôpitaux de Paris","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients with Denys-Drash syndrome",null,"Patients who were minors at the time of kidney transplantation between 2000 and 2022.",[13],"Other: Collection of data from the patient's medical file",{"label":15,"type":10,"description":16,"interventionNames":17},"Control patients","The controls will be matched in chronological order of transplantation with patients with Denys-Drash syndrome: a control before and a control after, matched according to the Epstein-Barr virus status of the pretransplant recipient, the Epstein-Barr virus status of the donor and the age of transplantation.",[13],[19],{"type":6,"name":20,"description":21,"armGroupLabels":22,"otherNames":10},"Collection of data from the patient's medical file","Collection of data from the patient's medical file. The data will be collected until 2024.",[15,9],[24],{"name":25,"affiliation":5,"role":26},"Mathilde M.D. Grapin","PRINCIPAL_INVESTIGATOR",[28,32],{"name":25,"role":29,"phone":30,"phoneExt":10,"email":31},"CONTACT","0033142192726","mathilde.grapin@aphp.fr",{"name":33,"role":29,"phone":34,"phoneExt":10,"email":35},"Hélène Morel","33171196346","helene.morel@aphp.fr",[37,55,68,77,86,99,110],{"facility":38,"status":10,"city":39,"state":10,"zip":40,"country":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Hôpital Femme Mère Enfant, Hospices Civils de Lyon","Bron","69500","France",{"type":43,"coordinates":44},"Point",[45,46],4.91303,45.73865,{"lat":46,"lon":45},[49,52],{"name":50,"role":29,"phone":10,"phoneExt":10,"email":51},"Justine MD, PhD Bacchetta","justine.bacchetta@univ-lyon1.fr",{"name":53,"role":29,"phone":10,"phoneExt":10,"email":54},"Anne-Laure M.D. Sellier","anne-laure.sellier-leclerc@chu-lyon.fr",{"facility":56,"status":10,"city":57,"state":10,"zip":58,"country":41,"cosmosGeoPoint":59,"geoPoint":63,"contacts":64},"CHU de Lille","Lille","59000",{"type":43,"coordinates":60},[61,62],3.05512,50.63391,{"lat":62,"lon":61},[65],{"name":66,"role":29,"phone":10,"phoneExt":10,"email":67},"Robert M.D. Novo","robert.novo@chu-lille.fr",{"facility":69,"status":10,"city":70,"state":10,"zip":71,"country":41,"cosmosGeoPoint":72,"geoPoint":76,"contacts":10},"CHU Montpellier","Montpellier","34000",{"type":43,"coordinates":73},[74,75],3.87635,43.61093,{"lat":75,"lon":74},{"facility":78,"status":10,"city":79,"state":10,"zip":80,"country":41,"cosmosGeoPoint":81,"geoPoint":85,"contacts":10},"CHU de Nancy - Hôpitaux de Brabois","Nancy","54500",{"type":43,"coordinates":82},[83,84],6.18496,48.68439,{"lat":84,"lon":83},{"facility":87,"status":10,"city":88,"state":10,"zip":89,"country":41,"cosmosGeoPoint":90,"geoPoint":94,"contacts":95},"Hôpital enfants et adolescents, CHU Nantes","Nantes","44093",{"type":43,"coordinates":91},[92,93],-1.55336,47.21725,{"lat":93,"lon":92},[96],{"name":97,"role":29,"phone":10,"phoneExt":10,"email":98},"Gwenaelle M.D. Roussey","gwenaelle.roussey@chu-nantes.fr",{"facility":100,"status":10,"city":101,"state":10,"zip":102,"country":41,"cosmosGeoPoint":103,"geoPoint":107,"contacts":108},"Hôpital Necker-Enfants Malades","Paris","75015",{"type":43,"coordinates":104},[105,106],2.3488,48.85341,{"lat":106,"lon":105},[109],{"name":25,"role":29,"phone":30,"phoneExt":10,"email":31},{"facility":111,"status":10,"city":101,"state":10,"zip":112,"country":41,"cosmosGeoPoint":113,"geoPoint":115,"contacts":116},"Hôpital Robert Debré","75019",{"type":43,"coordinates":114},[105,106],{"lat":106,"lon":105},[117],{"name":118,"role":29,"phone":10,"phoneExt":10,"email":119},"Julien MD, PhD Hogan","julien.hogan@aphp.fr",{"type":121,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[123],{"name":124,"class":6},"URC-CIC Paris Descartes Necker Cochin","100640340",false,"NCT07605884","Denys-Drash Syndrome and Risk of Post-transplant Lymphoproliferative Disorder","Post-transplant Lymphoproliferative Disorder Following Kidney Transplantation in Denys-Drash Syndrome: a Case-control Study","DRASH-PTLD","Inclusion Criteria:\n\n* Patient must be a minor at the time of kidney transplantation\n* Diagnosis of Denys-Drash syndrome (WT1 pathogenic variants in exons 8 or 9) for cases\n* Controls: minor patient, kidney transplanted at the same center as the case, immediately before and immediately after the case\n* Kidney transplant recipient on immunosuppressants\n* Hospital follow-up in a participating center in France\n* Regardless of their Epstein-Barr virus status before transplantation\n* Between 2000 and 2022\n* Holders of parental authority or adult patients informed of the study and not objecting to the processing of medical data for the study\n\nExclusion Criteria:\n\n* History of lymphoproliferative disorder prior to transplantation\n* Other hematopoietic cancer\n* Other genetic disease with a proven increased risk of lymphoproliferative disorder","ALL",{"count":134,"type":135},108,"ESTIMATED","OBSERVATIONAL","Denys-Drash syndrome is a rare genetic disorder of childhood characterized by nephrotic syndrome, nephroblastomas, and genital developmental abnormalities. These children present with rapidly progressive renal failure, leading to kidney transplantation at a median age of 3.6 years. In a study of the French cohort of patients with Denys-Drash syndrome, a high risk of lymphoproliferative syndrome was observed (20%). This frequency is significantly higher than in the general transplant population (4%).\n\nThe aim of the study is to evaluate the risk of post-transplant lymphoproliferative disorder following kidney transplantation in patients with Denys-Drash syndrome compared to patients with kidney transplant patients without Denys-Drash syndrome.",[139],"Denys-Drash Syndrome",[141,142,143],"Denys-Drash syndrome","Post-transplant lymphoproliferative disorder","Kidney transplantation","NOT_YET_RECRUITING","2026-05-18",{"date":147,"type":148},"2026-05-26","ACTUAL",{"date":150,"type":135},"2026-06",{"date":152,"type":135},"2027-06",{"name":5,"class":6},7]